Galaxy Biomedical Investment Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 246.29 million compared to CNY 322 million a year ago. Revenue was CNY 246.29 million compared to CNY 322 million a year ago.

Net loss was CNY 72.88 million compared to CNY 14.68 million a year ago. Basic loss per share from continuing operations was CNY 0.0663 compared to CNY 0.0133 a year ago. Diluted loss per share from continuing operations was CNY 0.0663 compared to CNY 0.0133 a year ago.